In this issue:
Benralizumab for eosinophilic granulomatosis with polyangiitis
Glucocorticoids + rituximab for ANCA-associated vasculitis
Rituximab for gene 5-positive juvenile dermatomyositis
Abatacept in juvenile idiopathic arthritis
IV immunoglobulin for active dermatomyositis
Circulating miR-146a and miR-155 and clinical response to TNF-α inhibition
Predictors of paradoxical reactions to biologic therapy
Guselkumab for axial-related symptoms in active PsA
Ixekizumab efficacy in severe peripheral PsA
Six-month persistence of guselkumab in PsA
Please login below to download this issue (PDF)